Accessibility Menu
Sangamo Therapeutics logo

Sangamo Therapeutics(NASDAQ) SGMO

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-100%
5 Year-99%
1 Year-89%
1 Month+44%
Sangamo Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.072026-07-24
Sangamo Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.072026-07-17
1 month+44.38%USD 0.052026-06-24
3 month-65.81%USD 0.192026-04-24
Year to date-84.52%USD 0.422025-12-31
1 year-89.12%USD 0.602025-07-24
3 year-95.19%USD 1.352023-07-25
5 year-99.35%USD 9.942021-07-23
Since inception-99.57%USD 15.062000-04-06

Sangamo Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$34.56M

Net Income (TTM)

-$123.33M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 6, 2026

SGMO News

genetics3

CRISPR 101: What Investors Need to Know

Matt Frankel, CFP®Jun 5, 2021
getty-woman-w-surgical-mask

3 Top Biotech Stocks to Watch in July

Alex CarchidiJul 9, 2020
Doctor blood vial

Pfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical Trial

Brian Orelli, PhDJun 18, 2020
GettyImages-1187059346

Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics

Alex CarchidiJun 14, 2020
Female scientist holding 2 test tubes

Better Buy: Cara Therapeutics vs. Sangamo Therapeutics

Keith SpeightsApr 29, 2020
GettyImages-1145759798

Better Buy: Editas Medicine vs Sangamo Therapeutics

Mark PrvulovicApr 1, 2020
GettyImages-1167797053

3 Top Stocks You've Probably Never Heard Of

Mark PrvulovicMar 28, 2020
GettyImages-1070162470

Better Buy: CRISPR Therapeutics vs. Sangamo Biosciences

David HaenMar 19, 2020
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is a biotechnology company specializing in genomic medicine. They focus on transforming chronic and debilitating conditions by pioneering gene-editing and gene therapy technologies.

Products and Services

Epigenetic regulation therapies for neurological diseases

Engineered adeno-associated virus (AAV) capsids for targeted drug delivery

Gene therapy product candidate for Fabry disease, ST-920

Gene therapy product candidate for Hemophilia A, giroctocogene fitelparvovec

Zinc finger protein (ZFP) technology platform for precise genomic alterations

What Makes Sangamo Therapeutics, Inc. Special

Sangamo stands out with its proprietary zinc finger protein (ZFP) technology, enabling high-specificity gene targeting. This provides a unique competitive edge in the genomic therapeutics field.

Five Things You Need to Know

They have strategic collaborations with major pharmaceutical companies like Pfizer and Genentech.

Their ST-920 product for Fabry disease has a clear path to Accelerated Approval from the FDA.

They leverage a strong intellectual property portfolio with numerous patents and pending applications.

Sangamo's gene therapy for Hemophilia A, giroctocogene fitelparvovec, is under a global Phase 3 trial.

They are advancing a novel AAV capsid engineering platform to enhance CNS-targeted drug delivery.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

142

CEO

Alexander D. Macrae, PhD

Website

www.sangamo.com

Headquarters

Richmond, CA 94804, US

SGMO Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

-862.17%

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$34.56M

Operating Income

-$110.32M

EBITDA

-$117.46M

Operating Cash Flow

-$90.34M

Capital Expenditure

-$115.00K

Free Cash Flow

-$90.46M

Cash & ST Invst.

$27.59M

Total Debt

$19.33M

Sangamo Therapeutics Performance Analysis

Sangamo Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 111,299,0000.5%
20232023-12-31USD 176,232,00058.3%
20242024-12-31USD 57,800,000-67.2%
20252025-12-31USD 39,552,000-31.6%
Sangamo Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30184.4%
Q32025-09-30-96.8%
Q42025-12-312348.9%
Q12026-03-31-89.9%
Sangamo Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.251.0%
20232023-12-31USD -1.4818.6%
20242024-12-31USD -0.49-67.1%
20252025-12-31USD -0.44-9.7%
Sangamo Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3044.4%
Q32025-09-30-41.4%
Q42025-12-31N/A
Q12026-03-3127.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.44M

-77.6%

Gross Profit

$1.44M

-77.6%

Gross Margin

100.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

127

N/A

Net Income

-$31.00M

-1.3%

EBITDA

-$30.12M

-5.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$27.59M

+9.6%

Total Debt

$19.33M

-22.3%

Accounts Receivable

$6.36M

+38.1%

Inventory

$0.00

N/A

Long Term Debt

$19.33M

-22.3%

Short Term Debt

$0.00

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$19.30M

+26.2%

Operating Cash Flow

-$19.28M

+26.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CCCCC4 Therapeutics, Inc.
$3.55+4.26%
IMDXInsight Molecular Diagnostics Inc.
$4.80+1.16%
OABIOmniAb, Inc.
$2.03-0.25%
CDXSCodexis, Inc.
$1.54+4.05%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.24+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.20-0.03%
AALAmerican Airlines Group
$14.59+0.01%
FFord Motor Company
$14.46+0.01%

Questions About SGMO

What is the current price of Sangamo Therapeutics?

Sangamo Therapeutics is trading at N/A per share.

What is the 52-week range for Sangamo Therapeutics?

Over the past 52 weeks, Sangamo Therapeutics has traded between N/A and N/A.

How much debt does Sangamo Therapeutics have?

As of the most recent reporting period, Sangamo Therapeutics reported total debt of $19.33M.

How much cash does Sangamo Therapeutics have on hand?

Sangamo Therapeutics reported $27.59M in cash and cash equivalents in its most recent financial results.

What is Sangamo Therapeutics’s dividend yield?

Sangamo Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services